CatalYm Presents Expanded Clinical and New Preclinical Data from
CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiati…
CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiati…
Biomax Informatics, PEPperPRINT and PMCR today announced the launch of a joint research project with partners from the U…
Das Paul-Ehrlich-Institut hat in Zusammenarbeit mit der Universität Frankfurt am Main die Langzeit-Antikörperreaktion na…
First four dose escalation levels completed showing excellent tolerability for CTL-002 as monotherapy and in combination…
4SC AG (4SC, FSE Prime Standard: VSC) today announced the results of a scheduled review of 4SC’s program for the clinica…
First Patient Enrolled in TURANDOT Study Evaluating Domatinostat in the Neoadjuvant Setting in Urothelial Carcinoma Comb…
. - MERKLIN1 study progress update - EMERGE phase IIa clinical data presentation - DONIMI phase Ib clinical data presen…
Prof. Dr. Andreas von Deimling erforscht am Universitätsklinikum Heidelberg (UKHD) und am Deutschen Krebsforschungszentr…
* MERKLIN1: Trial in progress e-poster (ID 123) and oral presentation entitled "A phase II, open label, multicenter stud…
Wissenschaftler:innen des Universitätsklinikums Hamburg-Eppendorf (UKE) veröffentlichen neueste Erkenntnisse aus klini…